Baidu
map

Medscape: 远程医疗实现丙肝专家与基层医师面对面

2014-05-19 佚名 dxy

根据5月9日Morbidity and Mortality Weekly Report的最新报道,一项由美国疾病预防控制中心(CDC)赞助的“丙肝计划”顺利在犹他州和亚利桑那州开展。 借助远程医疗技术,丙肝专家与农村或经济欠发达地区基层医师通过视频会议交流探讨病例,构建了长期合作框架。该计划成功锻炼出一批可熟练掌握丙肝病毒(HCV)感染者诊治技术的基层医师,实现“专家与基层医师面对面”信息共享,推

根据5月9日Morbidity and Mortality Weekly Report的最新报道,一项由美国疾病预防控制中心(CDC)赞助的“丙肝计划”顺利在犹他州和亚利桑那州开展。

借助远程医疗技术,丙肝专家与农村或经济欠发达地区基层医师通过视频会议交流探讨病例,构建了长期合作框架。该计划成功锻炼出一批可熟练掌握丙肝病毒(HCV)感染者诊治技术的基层医师,实现“专家与基层医师面对面”信息共享,推动了丙肝诊治的医疗进步。

1.“HCV计划”详情

这项CDC资助的计划于2012年9月在犹他州和亚利桑那州启动,以新墨西大学“社区医疗成果扩展”项目(ECHO)为蓝本,效仿ECHO通过远程医疗视频会议(teleECHO)形式,联通医学专家与农村或欠发达地区基层医师病例信息共享,提高整体医疗水平。

总体而言,共有66名基层医院内科医生参加了CDC的这项远程医疗提升计划,多数医生来自农村诊所和社区健康中心,其中93%缺乏HCV感染者诊治经验。每周teleECHO视频会议上,由当地医生汇报病例,与丙肝专家探讨诊治方案。

2012年9月30日至2014年2月28日项目开展期间,参与者和专家总共交流了280例特殊慢性HCV感染病例,所有患者均来自两个州、1945至1965年间美国本土出生、非西班牙裔白人。其中,129名(46.1%)患者开始接受治疗,91人(70.5%)给予干扰素为基础的治疗方案,34人(26.4%)尝试含2013年批准新药sofosbuvir的治疗方案。

ECHO计划中愿意开始接受治疗的患者比例远超预期,将近以往数据的2倍。来自CDC病毒性肝炎分部Kiren Mitruka博士认为,该种医疗模式能加强融洽基层医患关系,使患者相信基层医疗不仅有能力及时诊断,还能有效治疗;确保患者在医疗保健系统中从明确诊断到开始治疗过程中不迷失方向。

2.有望开展更多远程医疗

由于CDC于2012年大力推荐的丙肝筛查,涉及1945年至1965年间出生的人群,因此研究人员预计HCV感染诊断可能会出现一个激增阶段,而令人担忧的却是如何使明确诊断的患者及时得到有效治疗。

Mitruka认为,在HCV感染管理过程中,除了新近涌现的各种耐受性良好的治疗方案外,医疗系统还需要努力提升基层医务人员的诊疗水平,这不是个人能独立完成的事情,而是需要加强专家与基层医疗机构构建HCV感染诊治的合作,同时建立有序的公共卫生管理体系。

研究人员基于询证医学对ECHO计划进行评估,发现计划中参与治疗的患者预后与专业医学中心诊治的患者预后相似。Mitruka点评认为,该研究向人们传达了一个讯息,即这两个州能够成功复制这种远程医疗模式;而不足之处在于尚缺乏足够证据支持向其它州的可推广性。

研究人员总结认为,加强与专家的合作交流,能够促进基层医师开始将新治疗方法逐步整合到HCV感染管理中,这将是提高丙肝诊疗水平及打破信息交流壁垒的重要医疗对策。本次ECHO计划评估结果显示,这样的新型医疗模式能有效改善欠发达地区人群HCV感染诊疗,给该人群丙肝患者带来福音。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1897953, encodeId=3d1a189e953aa, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jul 02 02:58:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725609, encodeId=73e41e2560912, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 02 07:58:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350952, encodeId=6ff413509527c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458553, encodeId=b29914585530e, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606186, encodeId=4bfe16061860a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=)]
    2014-07-02 smlt2008
  2. [GetPortalCommentsPageByObjectIdResponse(id=1897953, encodeId=3d1a189e953aa, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jul 02 02:58:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725609, encodeId=73e41e2560912, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 02 07:58:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350952, encodeId=6ff413509527c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458553, encodeId=b29914585530e, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606186, encodeId=4bfe16061860a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=)]
    2014-07-02 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1897953, encodeId=3d1a189e953aa, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jul 02 02:58:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725609, encodeId=73e41e2560912, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 02 07:58:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350952, encodeId=6ff413509527c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458553, encodeId=b29914585530e, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606186, encodeId=4bfe16061860a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=)]
    2014-05-21 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1897953, encodeId=3d1a189e953aa, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jul 02 02:58:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725609, encodeId=73e41e2560912, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 02 07:58:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350952, encodeId=6ff413509527c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458553, encodeId=b29914585530e, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606186, encodeId=4bfe16061860a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1897953, encodeId=3d1a189e953aa, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jul 02 02:58:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725609, encodeId=73e41e2560912, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 02 07:58:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350952, encodeId=6ff413509527c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458553, encodeId=b29914585530e, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606186, encodeId=4bfe16061860a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 21 07:58:00 CST 2014, time=2014-05-21, status=1, ipAttribution=)]

相关资讯

MDLive:远程医疗在美国迅速开花

自从离开苹果之后,约翰·斯卡利就投身投资业,凭借出色的商业嗅觉帮助不少公司上市或者被收购。在过去的十余年里,斯卡利将重心放在健康医疗领域,在他看来,这个领域即将迎来变革。 他已经投资了或共同创办了多家健康领域的公司,包括专门生产睡眠呼吸暂停诊断仪的Watermark Medical,健康生活保险公司Audax Health Solution,以及投资了Misfit可穿戴设备公司,还有最近刚刚

美国未来五年远程医疗总营收有望达20亿美元

从医生短缺到《平价医疗法案》(Affordable Care Act)下供应商收费方式的改变,在医疗产业这些事件的共同影响下,未来五年内,美国远程医疗业务的总营收有望达到近20亿美元。通过各种设备、计算机及相关数字技术,远程医疗使得医生与其他供应商能够对病人实施远程监护。而据信息与分析公司IHS最新的一份报告显示,到2018年时美国远程医疗领域的营收将从今年的2.4亿美元增至19亿美元。远程医疗这

两部委开展远程医疗试点 移动医疗迎春天

发改委网站24日消息,为贯彻落实中共中央第十八届三中全会关于“充分利用信息化手段,促进优质医疗资源纵向流动”的精神,以及医药卫生体制改革和促进信息消费扩大内需的相关工作部署,经征求有关部门和地方意见,国家发展改革委、国家卫生计生委决定组织开展省院合作远程医疗政策试点工作。 试点工作将重点针对制约我国远程医疗发展的政策环境障碍,在远程医疗的操作规范、责任认定、激励机制、收费、医疗费用报销等方面,研

Baidu
map
Baidu
map
Baidu
map